A Selection of Recent Papers

Meta-data Analysis as a Strategy to Evaluate Individual and Common Features of Proteome Changes in Breast Cancer. O. ZAKHARCHENKO, C. GREENWOOD, A. LEWANDOWSKA, U. HELLMAN, L. ALDREDGE, S. SOUCHELNYTSKYI (Stockholm; Uppsala, Sweden; Chelmsford, UK; Gliwice, Poland; Gold Coast, QLD, Australia)

Circadian Transcription Profile of Mouse Breast Cancer under LD and DD Conditions. E.-Y.OH, X.YANG, A. FRIEDMAN, C.M. ANSELL, J. DUQUINTON, D.F. DUQUINTON, P.A.WOOD, W.J.M.HRUSHESKY (Columbia, SC; St. Louis, MO, USA)

Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer. U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (Munich, Germany)

A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression. R. HUANG, W. JIANG, J. YANG, Y.Q. MAO, Y. ZHANG, W. YANG, D. YANG, B. BURKHOLDER, R.F. HUANG. R.-P.HUANG (Norcross, GA, USA; Guangzhou, P.R.China)

TGF-β1 Interactome: Metastasis and Beyond. M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAI, M.G. SMITH, A.J. TRACHTENBERG, W.P.KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A.SCHULZ (Düsseldorf, Germany)

Molecular Profiling Using Tissue Micrarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSON, S. EKMAN, J. REIZENSTEIN, R.F. HUANG. R.-P.HUANG (Norcross, GA, USA; Guangzhou, P.R.China)

Proteomic Study of Sera from Patients with Bladder Cancer: Usefulness of S100A8 and S100A9 Proteins. S. MINAMI, Y. SATO, T. MATSUMOTO, T.KAGEYAMA, Y. KAWASHIMA, K. YOSHIO, I. OKAYASU (Tokyo, Japan)

Analysis of Protein Phosphorylation in Cisplatin-treated Human Cells Following Annexin V-based Separation and Multi-Antibody Screening. E. O’MEARA, S. CRUET-HENNEQUART, M.P. CARTY (Galway, Ireland)


DNA-based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J.A. ALRUWAILI, S. ET. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, C.L. AUKIM-HASTIE, P.A. TOWNSEND (Hampshire, UK; Riyadh, Kingdom of Saudi Arabia; Boston, MA, USA)

Effects of Artesunate on Cytokinesis and G2/M Cell Cycle Progression of Tumour Cells and Budding Yeast. L. STEINBRUCK, G. PEREIRA, T. EFFERTH (Heidelberg; Mainz, Germany)

Use of NG2 (7.1) in AML as a Tumor Marker and its Association with a Poor Prognosis. K. PETROVICI, M. GRAF, K. HECHT, S. REIF, K. PFISTER, H. SCHMETZER (Regensburg; Munich, Germany)
**Instructions to Authors**

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

**Tables.** Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI. J. OCVIRK, M. REBERSEK, M. BOC (Ljubljana, Slovenia) .................................................. 1777

Differences in Breast Carcinoma In Situ Between Menopausal and Premenopausal Women. C. PRADIER, M. CORNUAU, J. NORCA, H. MESBAH, P. POREE, G. BODY, J.-M. CLASSE, J. LEVEQUE (Rennes; Tours; Nantes, France) ................................................................. 1783

Fundic Gland Polyps. C.A. RUBIO, G. NESI (Stockholm, Sweden) ................................................................................. 1789


Assessment of General Anxiety in Patients with Breast Disease and Breast Cancer Using the Spielberger STAI Self Evaluation Test: A Prospective Case-Control Study in Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) ........................................................................................................................................ 1801


ABSTRACTS OF THE 15th INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS, Hamburg, Germany, 29-31 May, 2011 ........................................................................................................ 1957

* Reviews (pages 1515, 1795)


Gene Mutations and Polymorphisms of TP53 and FHIT in Chronic Esophagitis and Esophageal Carcinoma. A.P.F. SILVEIRA, F. MANOEL-CAETANO, S. AOKI, L.H.T. YAMASAKI, P. RAHAL, A.E. SILVA (São José do Rio Preto, SP, Brazil) ........................................................................................................ 1685

Phenethyl Isothiocyanate (PEITC) Promotes G2/M Phase Arrest via p53 Expression and Induces Apoptosis through Caspase- and Mitochondria-dependent Signaling Pathways in Human Prostate Cancer DU 145 Cells. N.-Y. TANG, Y.-T. HUANG, C.-S. YU, Y.-C. KO, S.-H. WU, B.-C. JI, J.-S. YANG, J.-L. YANG, T.-C. HSIA, Y.-Y. CHEN, J.-G. CHUNG (Taichung; Chiayi; Changhua, Taiwan, ROC) ........................................ 1691


Clinical Studies

Impact of Common Medications on Serum Total Prostate-specific Antigen Levels and Risk Group Assignment in Patients with Prostate Cancer. C. NIEDER, J. NORUM, H. GEINITZ (Bodo; Tromsø, Norway; Munich, Germany) ........................................................................................................ 1735

Iron Chelation Therapy with Deferasirox Induced Complete Remission in a Patient with Chemotherapy-resistant Acute Monocytic Leukemia. T. FUKUSHIMA, H. KAWABATA, T. NAKAMURA, H. IWAO, A. NAKAJIMA, M. MIKI, T. SAKAI, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA (Ishikawa; Kyoto, Japan) .................................................................................................................. 1741


Pemetrexed-induced Hyperpigmentation of the Skin. D. SCHALLIER, L. DECOSTER, J. DE GREVE (Brussels, Belgium) .......................................................................................................................... 1753

Lymphatic Microvessel Density, VEGF-C, and VEGFR-3 Expression in Different Molecular Types of Breast Cancer. M. RAICA, A.M. CIMPEAN, R. CEASU, D. RIBATTI (Timisoara, Romania; Bari, Italy) .................................................................................................................. 1757

Off-label Use of Oxaliplatin in Patients with Metastatic Breast Cancer. A. DELPEUCH, D. LEVEQUE, L. ROB, J.-P. BERGERAT (Strasbourg, France) .................................................................................................................. 1765
Pretreatment HIF-1α and GLUT-1 Expressions Do Not Correlate with Outcome after Preoperative Chemoradiotherapy in Rectal Cancer. B.M. Havelund, F.B. Sørensen, J. Lindebjerg, K.-L.G. Spindler, A. Jakobsen (Vejle, Denmark) ........................................................................................................ 1559

Heterogeneity of Metalloproteinase Expression in Colorectal Cancer – Relation of Molecular Findings to Basic Morphology. Y. Kajiwara, H. Ueno, Y. Hashiguchi, E. Shinto, H. Shimazaki, H. Mochizuki, K. Hase (Saitama, Japan) .......................................................................................... 1567


Lectin Histochemistry of Metastasizing and Non-metastasizing Breast and Colon Cancer Cells. B. Schnegelsberg, U. Schumacher, U. Valentiner (Hamburg, Germany) ........................................................................................................ 1589

Structural Rearrangements of Trisomies Are a Risk Marker of Clinical Progression in Hyperdiploid Multiple Myeloma. R. Alfaro, J. Rosell, M.A. Durán, G. Puget, J. Besalduch, P. Galán, A. Vallés, M. Bernués (Mallorca; Menorca, Spain) ........................................................................................................ 1599

Correlation and Coexpression of HIFs and NOTCH Markers in NSCLC. S. Andersen, T. Donnem, S. Alsaad, K. Al-Shibli, H. Stenvold, L.-T. Busund, R.M. Brennes (Tromso; Bodo, Norway) .............................................................. 1603

NF-κB Activation by Peroxynitrite through IκBα-dependent Phosphorylation versus Nitration in Colon Cancer Cells. E. Gochman, J. Mahajna, A.Z. Reznick (Haifa; Kiryat Shmona, Israel) ........................................................................................................ 1607

Efficient Down-regulation of CDK4 by Novel Lipid Nanoparticle mediated siRNA Delivery. X. Wang, B. Yu, Y. Wu, R.J. Lee, L.J. Lee (Beijing, PR China; Columbus, OH, USA) ........................................................................................................ 1619


Experimental Study of the Anticancer Effect of Gemcitabine Combined with Sirolimus on Chemically Induced Urothelial Lesions. C. Vasconcelos-Nóbrega, A. Colaço, L. Santos, H. Vala, L.F. Palomino, C. Lopes, P.A. Oliveira (Viseu; Vila Real; Porto; Portugal; Lugo, Spain) ........................................................................................................ 1637

p16INK4a Methylation in Serum as a Follow-up Marker for Recurrence of Colorectal Cancer. G. Nakayama, Y. Kodera, N. Ohashi, M. Koike, M. Fujiwara, A. Nakao (Nagoya; Aichi, Japan) ........................................................................................................ 1643

Barley Low Molecular Weight β-Glucan Potently Induces Maturation of Mouse Dendritic Cells. A. Tanioka, W.-W. An, T. Kuge, K. Tsukabaki, K. Nakaya (Tokyo; Niigata, Japan) ........................................................................................................ 1647


Zeranol Induces Cell Proliferation and Protein Disulphide Isomerase Expression in Mammary Gland of ACI Rat. S. Zhong, W. Ye, S.-H. Lin, J.-Y. Liu, J. Leong, C. Ma, Y.C. Lin (Beijing, PR China; Columbus, OH, USA) ........................................................................................................ 1659